Columbia-based Osiris Therapeutics Inc., a biotechnology company developing stem cell-based treatments, beat Wall Street analysts' estimates with a reported loss of $4.3 million in the second quarter, which ended June 30.
The firm, which earlier this year drew international headlines for having the world's first stem cell drug approved by a major country, posted a loss of 13 cents per share. Analysts polled by MarketWatch had expected a 15-cent-per-share loss. The company said its revenues from biosurgery products — which are used to improve wound healing and tissue regeneration — rose 43 percent, to $1.6 million, from the first quarter.
Total revenue for the second quarter was $10.4 million, a $200,000 increase over the year-earlier period. The company expects revenues to grow in coming years from the sale of Prochymal, the stem cell drug approved in Canada earlier this year to fight graft-versus-host disease in bone marrow transplant patients.
The company has about $40 million in cash on hand.
Gus.sentementes@baltsun.com
Text BUSINESS to 70701 to get Baltimore Sun Business text alerts
The firm, which earlier this year drew international headlines for having the world's first stem cell drug approved by a major country, posted a loss of 13 cents per share. Analysts polled by MarketWatch had expected a 15-cent-per-share loss. The company said its revenues from biosurgery products — which are used to improve wound healing and tissue regeneration — rose 43 percent, to $1.6 million, from the first quarter.
The company has about $40 million in cash on hand.
Gus.sentementes@baltsun.com
Text BUSINESS to 70701 to get Baltimore Sun Business text alerts
